Stephen B. Hanauer MD, MACGClifford Joseph Barborka Professor of Medicine, Northwestern University Feinberg School of Medicine; Medical Director, Digestive Health Center, Northwestern Medicine, Chicago, Illinois
Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 1999, he was named the Joseph B. Kirsner Chair in Medicine and was designated Chief of the Section of Gastroenterology, Hepatology and Nutrition at the University of Chicago from 1999-2014. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.
Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. He is also a prior member of the Gastroenterology Specialty Board of the American Board of Internal Medicine and is a member and former-Chairman of the International Organization for Inflammatory Bowel Disease. Among his many honors, Dr. Hanauer received the AGA’s Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology and the Janssen Award for Clinical Excellence. He has served as a member of the U.S. FDA Gastrointestinal Drugs Advisory Committee since 1987, he Chaired the Committee from 1998-2000, and he presently serves the Center for Drug Development and Research as a Special Consultant defining new guidelines for clinical evaluation of IBD patients. In February 2020, received the “Great Teachers” Award from the National Institute of Health (NIH) and in October 2020, received the Master of the American College of Gastroenterology.
Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.
Dr. Hanauer has authored over 475 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He is the former-Editor-in-Chief of Nature Clinical Practice Gastroenterology & Hepatology and has served as on the editorial boards of Clinical Gastroenterology and Hepatology, American Journal of Gastroenterology and Inflammatory Bowel Diseases. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.
In addition to his passion for clinical care, Dr. Hanauer considers his greatest accomplishment to be the mentorship of numerous trainees and young faculty. He is extremely proud of the successes of such notable trainees as Brett Lashner (prior editor IBD), Sunanda Kane (past ACG president), Laura Raffals (Mayo Clinic), David Rubin (CCF, Russel Cohen, Geert D’Haens (Amsterdam, prior president of ECCO), Filip Baert (Leuven Belgium), Miles Sparrow (Melbourne, Australia), Scott Lee (U. Washington), Themos Dassopoulos (Baylor), Henit Yanai (Jerusalem), amongst many other local, regional, national, and international IBD experts. They will forever be his most relevant legacy.
DisclosuresNo disclosures reported.
Recent Contributions to PracticeUpdate:
- Mirikizumab as Induction and Maintenance Therapy in Patients With Ulcerative Colitis
- Increasing Incidence of Pouchitis Between 1996 and 2018 Among Patients With Ulcerative Colitis
- Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease
- Mongersen More Effective Than Placebo for Crohn's Disease